Literature DB >> 7577463

Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis.

S de Kossodo1, R Moore, S Gschmeissner, N East, C Upton, F R Balkwill.   

Abstract

The aim of this study was to investigate mechanisms of anti-tumour activity and necrosis induced by combinations of tumour necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma). In a breast cancer xenograft model, locally injected recombinant human TNF-alpha arrested growth of established tumours in the absence of overt necrosis. Macroscopic necrosis occurred when rat IFN-gamma, which had no anti-tumour activity as a single agent, was given systemically. Treatment with TNF-alpha and IFN-gamma caused focal engorgement of tumour capillaries with erythrocytes, intravascular recruitment of polymorphonuclear cells and platelet adherence to the tumour vascular endothelium 4 h after the combined treatment. This was followed by destruction of tumour vascular endothelium and both necrosis and apoptosis of tumour cells. Concomitant with these changes, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis revealed the increase of stromal (murine) mRNA levels for TNF-alpha, TNF receptor 55 kDa, TNF receptor 75 kDa, intracellular adhesion molecule 1, vascular cell adhesion molecule 1, P-selectin and interleukin 6 (IL-6). Thus, the effect of the combined TNF-alpha and IFN-gamma therapy involved the selective destruction of the tumour vasculature, death of tumour cells and increased expression of a series of stromal cytokines, cytokine receptors and adhesion molecules, which could be implicated in the observed events.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577463      PMCID: PMC2033935          DOI: 10.1038/bjc.1995.481

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon.

Authors:  J S Pober; M A Gimbrone; L A Lapierre; D L Mendrick; W Fiers; R Rothlein; T A Springer
Journal:  J Immunol       Date:  1986-09-15       Impact factor: 5.422

2.  Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines.

Authors:  L Fransen; M R Ruysschaert; J Van der Heyden; W Fiers
Journal:  Cell Immunol       Date:  1986-06       Impact factor: 4.868

3.  Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.

Authors:  F R Balkwill; A Lee; G Aldam; E Moodie; J A Thomas; J Tavernier; W Fiers
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity.

Authors:  R A Dempsey; C A Dinarello; J W Mier; L J Rosenwasser; M Allegretta; T E Brown; D R Parkinson
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

6.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.

Authors:  D Liénard; A M Eggermont; H Schraffordt Koops; B B Kroon; F Rosenkaimer; P Autier; F J Lejeune
Journal:  Melanoma Res       Date:  1994-03       Impact factor: 3.599

7.  TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction.

Authors:  G E Grau; F Tacchini-Cottier; C Vesin; G Milon; J N Lou; P F Piguet; P Juillard
Journal:  Eur Cytokine Netw       Date:  1993 Nov-Dec       Impact factor: 2.737

8.  Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.

Authors:  A K Thom; H R Alexander; M P Andrich; W C Barker; S A Rosenberg; D L Fraker
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

9.  Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants.

Authors:  J A Barbara; W B Smith; J R Gamble; X Van Ostade; P Vandenabeele; J Tavernier; W Fiers; M A Vadas; A F Lopez
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  5 in total

1.  Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation.

Authors:  Kavitha Viswanathan; Firdaus S Dhabhar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-07       Impact factor: 11.205

2.  Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy.

Authors:  G A Limb; L Webster; H Soomro; S Janikoun; J Shilling
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

3.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

Authors:  P T Nooijen; E R Manusama; A M Eggermont; L Schalkwijk; J Stavast; R L Marquet; R M de Waal; D J Ruiter
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

4.  To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator.

Authors:  Daniela Sorriento; Maddalena Illario; Rosa Finelli; Guido Iaccarino
Journal:  Transl Med UniSa       Date:  2012-10-11

5.  Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma.

Authors:  Y Nakano; W Kobayashi; S Sugai; H Kimura; S Yagihashi
Journal:  Jpn J Cancer Res       Date:  1999-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.